Skip to main content
Premium Trial:

Request an Annual Quote

Affomix and City of Hope Partner on Ab Selection for Next-Gen Sequencing

NEW YORK (GenomeWeb News) – Affomix said today that it will collaborate with City of Hope to establish the clinical utility of "digital proteomics" using next-generation sequencers.

As part of the collaboration, Affomix will use its high-throughput, automated antibody-selection technology to provide City of Hope with recombinant antibodies that are designed to be readily tagged with oligonucleotide "zipcodes," making them compatible with next-generation sequencers.

Affomix, based in Branford, Conn., can optimize its antibody-selection technology to be compatible with any next-generation sequencer on the market, according to John Boyce, a co-founder of Delphi Bio, which provides business development services to Affomix, as well as head of business development for Affomix.

City of Hope will then use Affomix's recombinant antibodies to generate proteomic profiles characteristic of a number of cancers, such as renal and prostate.

"We are looking forward to exploring next-generation sequencing and the Affomix technology in diagnostics. Digital proteomics is the next frontier in personalized medicine," Jakub Sram, director of business development for City of Hope’s Molecular Diagnostic Laboratory, said in a statement.

"Collaborations with leading institutes such as City of Hope will enable us to expand our reach into the clinical diagnostics and personalized medicine markets," Boyce said in a statement. "This is a transformative milestone in the merging of proteomics and genomics."